Recruiting

Elranatamab

Sponsor:

Pfizer

Code:

NCT06057402

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elranatamab

Study Details

Brief summary:

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Conditions

Multiple Myeloma

Study ID

NCT06057402

Start date

Oct 3, 2023

Status verified date

Jun, 2026

Completion date

Feb 22, 2032

Anticipated

Primary completion date

Feb 22, 2032

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must agree to follow the reproductive criteria as outlined in the protocol
  • Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Exclusion Criteria:

  • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Study Design

Enrollment

80 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Elranatamab

Elranatamab is a heterodimeric humanized full length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells

Interventions

Elranatamab

Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells

Primary outcome measure

  • Incidence of nonserious adverse events (AEs) leading to permanent discontinuation [ Time Frame: A minimum of 90 days after the last dose of study drug ]
  • Incidence of serious adverse events (SAEs) [ Time Frame: A minimum of 90 days after the last dose of study drug ]

Central Contacts and Locations

Central contacts

Pfizer CT.gov Call Center

1-800-718-1021ClinicalTrials.gov_Inquiries@pfizer.com

Locations

UCI Health - Irvine Infusion Pharmacy ACC

Recruiting

Irvine, California, United States, 92612

UC Irvine Health

Recruiting

Orange, California, United States, 92612

UCI Health

Recruiting

Orange, California, United States, 92868

UCHealth Poudre Valley Hospital

Recruiting

Fort Collins, Colorado, United States, 80524

UCHealth Harmony

Recruiting

Fort Collins, Colorado, United States, 80528

UCHealth Greeley Hospital

Recruiting

Greeley, Colorado, United States, 80634

Longs Peak Hospital

Recruiting

Longmont, Colorado, United States, 80504

UCHealth Longs Peak Medical Center

Recruiting

Longmont, Colorado, United States, 80504

UCHealth - Medical Center of the Rockies

Recruiting

Loveland, Colorado, United States, 80538

Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

Recruiting

Coral Gables, Florida, United States, 33146

University of Miami Hospital and Clinics Deerfield Beach

Recruiting

Deerfield Beach, Florida, United States, 33442

Sylvester Comprehensive Cancer Center

Recruiting

Miami, Florida, United States, 33136

University of Miami Hospital and Clinics - Griffin Cancer Research Building

Recruiting

Miami, Florida, United States, 33136

University of Miami Hospital and Clinics

Recruiting

Miami, Florida, United States, 33136

University of Michigan

Recruiting

Ann Arbor, Michigan, United States, 48109

Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)

Recruiting

Detroit, Michigan, United States, 48202

St. David's South Austin Medical Center

Recruiting

Austin, Texas, United States, 78704

Arthur J.E. Child Comprehensive Cancer Centre

Recruiting

Calgary, Alberta, Canada, T2N 5GN

Cross Cancer Institute

Recruiting

Edmonton, Alberta, Canada, T6G 1Z2

McGill University Health Centre

Recruiting

Montreal, Quebec, Canada, H4A 3J1

More Information

Sponsor

Pfizer

Last update posted

Jul 1, 2026

Last verified

Jun, 2026

Keywords

  • Multiple Myeloma
  • Elranatamab
  • Post Trial Access
  • Roll-over Study
  • Extension Study
  • MM-15
  • MagnetisMM15
  • BCMA
  • BCMA antibody
  • Magnetism
  • Bispecific antibody
  • Elrexfio

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Pfizer on 2026-07-01.